Stocktoria

BIOLIFE SOLUTIONS INC BLFS

Nasdaq · XNAS · stock · Electromedical & Electrotherapeutic Apparatus
Chart by TradingView
6/9
Piotroski F — financial health
10.32
Altman Z″ — distress risk · safe
Dividend payout · no dividend

Financials (annual, from 10-K)

FYRevenueNet incomeGross profitFree cash flowEquity
2025$96.2M-$4.6M$62.1M$10.6M$371.9M
2024$74.6M-$20.2M$50.1M$5.2M$348.9M
2023$68.0M-$68.0M$41.3M-$18.9M$337.7M
2022$76.2M-$139.8M-$18.9M$364.2M
2021$119.2M-$8.9M-$13.0M$478.0M
2020$48.1M$2.0M$4.7M$204.4M

Recent insider activity (Form 4)

InsiderRoleDateActionSharesPrice
Werner SeanChief Technology Officer2026-06-18Tax withheld420$26.04
Berard ToddChief Marketing Officer2026-06-18Tax withheld470$26.04
DE GREEF RODERICKPresident and CEO2026-06-18Tax withheld2,775$26.04
Wichterman TroyChief Financial Officer2026-06-18Tax withheld937$26.04
Mathew Aby J.EVP & Chief Scientific Officer2026-06-18Tax withheld564$26.04
Berard ToddChief Marketing Officer2026-06-08Tax withheld356$26.10
Wichterman TroyChief Financial Officer2026-06-08Tax withheld1,026$26.10
Mathew Aby J.EVP & Chief Scientific Officer2026-06-08Tax withheld627$26.10

Why these scores methodology →

Piotroski F-score: 6/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: 10.32 (safe)

  • Working capital / assets 0.28
  • Retained earnings / assets -0.837
  • EBIT / assets -0.041
  • Equity / liabilities 10.939

Source: SEC EDGAR filings · CIK 0000834365 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.